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INTRODUCTION
Malignant tumor of the salivary gland is rather uncommon and
accounts for less than 0.3% of all malignancies. The overall inci-
dence in the United States is about 1.2 per 100,000 populations
per yr (1). Salivary cancer is heterogeneous with respects to histo-
logic type and biologic behavior. Surgical resection is the main-
stay of treatment, and several retrospective studies revealed that
the addition of postoperative radiation therapy (RT) in selected
patients improved both local control and survival (2-6). The clini-
cal indications of postoperative RT, in general, include pT3-4
disease, positive or close resection margin, bone invasion, per-
ineural invasion (PNI), high-grade histology, and regional lymph
node (LN) metastases (3, 7-9). Elective neck irradiation (ENI) is
optionally considered for large and high-grade tumors (8-10).
Objectives. This is to report treatment results of major salivary gland cancer by surgery with or without postoperative
radiation therapy (PORT). 
Methods. Between March 1995 and January 2006, 94 patients with primary major salivary cancer underwent curative
surgical resection at Samsung Medical Center. The parotid gland was the most commonly involved (73, 77.7%),
followed by the submandibular and the sublingual. Neck dissection was added in 28 patients, and PORT was indi-
vidually recommended to those with risk factors. Seventy-five (79.8%) patients received PORT. PORT volume
included primary tumor bed and pathologically involved regional lymphatics, and no additional effort was made for
elective nodal irradiation. The median total doses were 56.0 Gy to primary site and 58.7 Gy to regional lymphatics.
Results. After median follow-up of 49 months, 21 patients had relapsed: 20 in PORT; and one in surgery alone group. As
the first site of failure, distant metastasis was the most common (17 patients). Local recurrence occurred in three, and
regional relapse in one. The lung was the most common site (10 patients), followed by the bone, and the brain. Five-
yr disease free survival (DFS), local control, and overall survival (OS) rates were 74.4% and 94.7%, 96.0% and
100%, and 78.2% and 100% in PORT and surgery alone groups, respectively. On multivariate analysis, DFS was
significantly affected by pN+ (hazard ratio [HR], 3.624; P=0.0319), while OS was by pN+ (HR, 7.138; P=0.0034)
and perineural invasion (HR, 5.073; P=0.0187).
Conclusion. Based on our experience, the patients with early stage major salivary gland cancer with low risk can be
effectively treated by surgery alone, and those who with risk factors can achieve excellent local and regional con-
trol by adding PORT. Omitting elective neck irradiation in patients with N0 disease seems a feasible strategy
under accurate clinical evaluation. An effort is needed to decrease distant metastasis through further clinical trials.
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accurate diagnosis and optimal treatment planning: computed
tomography (CT), magnetic resonance imaging (MRI), and fluo-
rine-18 fluorodeoxyglucose (18F-FDG) whole-body positron emis-
sion tomography (PET) help identification of LN metastases with a
sensitivity of 80% to 90% and a specificity of 79% to 94% (11);
and three-dimensional conformal radiation therapy (3D CRT) and
intensity-modulated radiation therapy (IMRT) enable more con-
formal target coverage with sparing of the normal tissue (12).
The purpose of this study is to report our treatment experi-
ence of the patients with major salivary gland cancer, who were
treated with surgical resection with or without postoperative RT,
and to identify the predictors of outcomes.
MATERIALS AND METHODS
Between March 1995 and January 2006, 94 patients with newly
diagnosed major salivary gland carcinoma with no distant metas-
tasis underwent curative surgical resection at Samsung Medical
Center. The median age was 50 yr (range, 9 to 79 yr) and there
was male preponderance (59.6%, 56 patients). The parotid gland
was most commonly involved in 73 patients (77.7%), followed by
the submandibular gland in 16 (17.0%) and the sublingual gland
in five (5.3%) (Table 1). Surgical procedures included curative
resection of the involved gland in all patients, and some form of
neck node dissection was added in 28 patients (29.8%) (Table 2).
The indication of neck dissection and the decision about type of
neck dissection was individualized according to primary tumor
site and extent, lymphatic drainage, and clinically involvement
of lymph node. At the time of diagnosis, all patients received CT
evaluation and some of them received MRI (20 patients) or 18F-
FDG PET (21 patients) selectively. 
The histologic types are presented in Table 1. Among the 27
patients with mucoepidermoid carcinoma, 19 patients had low-
grade tumor and the remaining 8 patients had intermediate or
high grade tumor. We considered low-grade mucoepidermoid and
acinic cell carcinoma as low-grade tumors, and the other subtypes
were considered high-grade. About three fourths of all (73.4%, 69
patients) were with high-grade tumors. The pathologic T-stages
according to American Joint Committee on Cancer (AJCC) 6th
2002 are presented in Table 3. Among the 28 patients who under-
went neck dissection, 15 (16.0%) had pathologically positive neck
node: pN1 in six (6.4%); and pN2 in nine (9.6%). Based on the
distribution of characteristics among the patients did or did not
receive postoperative RT, those who received postoperative RT
had high-grade tumors more frequently (Table 1).
The addition of postoperative RT was considered and indi-
vidually recommended to the patients with one or more of the
following risk factors: high-grade histology; positive or close
(<5 mm) resection margin; PNI; lymphovascular invasion (LVI);
extraparenchymal extension (EPE); T3-4 disease; and positive
regional LN. The criteria of EPE were according to AJCC 6th
2002. The actual numbers of patients who did and did not receive
postoperative RT were 75 (79.8%), and 19 (20.2%), and the
postoperative RT group had more patients with risk factors
(Table 3).
Postoperative RT was delivered with 4- or 6-MV photons
generated from linear accelerator. The RT volume was to include
the primary tumor bed and pathologically involved regional lym-
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Surgery + Surgery 
Characteristics postoperative RT alone
(n=75) (n=19)
Table 1. Patients’ characteristics
Median age (yr) 52 46
Gender
Male 46 (61.3) 10 (52.6)
Female 29 (38.6) 9 (47.4)
Location
Parotid gland 56 (74.7) 17 (89.4)
Submandibular gland 15 (20.0) 1 (5.3)
Sublingual gland 4 (5.3) 1 (5.3)
Histology
Mucoepidermoid carcinoma 18 (24.0) 9 (47.4)
Adenoid cystic carcinoma 18 (24.0) 2 (10.5)
Salivary duct carcinoma 12 (16.0) 1 (5.3)
Carcinoma ex  10 (13.3) 1 (5.3)
pleomorphic adenoma
Adenocarcinoma 8 (10.7) 0
Acinic cell carcinoma 2 (2.7) 5 (26.3)
Other 7 (9.3) 1 (5.3)
Grade
Low* 13 (17.3) 12 (63.2)
High 62 (82.7) 7 (36.8)
Values are presented as number (%).
*Low grade mucoepidermoid carcinoma and acinic cell carcinoma.
RT: radiation therapy.  
Surgery + Surgery 
postoperative RT alone
Table 2. Type of surgical resection
Primary site
Excision 31 2
Superficial parotidectomy 22 11
Total parotidectomy 22 6
Neck dissection
Modified radical neck dissection 6
Radical neck dissection 3
Selective neck dissection
Level I-III 10 1
Level II 4
Level I-II 3
Level I-IV 1
RT: radiation therapy.  phatics with adequate margins, and no additional effort was made
for ENI. CT-based contouring and radiation dose calculation were
performed using computerized planning software. The median
total doses to the primary site (75 patients) and the regional lym-
phatics (20 patients) were 56.0 Gy (range, 54 to 70 Gy) and 58.7
Gy (range, 40 to 66 Gy), with a fraction dose of 1.8 Gy (7 patients)
or 2.0 Gy (68 patients).
The median follow-up duration, calculated from the date of
surgery, was 49 months (range, 6 to 148 months). Complications
during or after postoperative RT were scored by the Radiation
Therapy Oncology Group (RTOG) criteria. The Kaplan-Meier
method was used to estimate the probability of disease-free sur-
vival (DFS), local control (LC), and overall survival (OS). The
comparisons of survival rates among the groups were done using
the log rank test. The Cox proportional hazard regression analy-
sis was used for multivariate analysis. A probability value of
less than 0.05 was considered statistically significant.
RESULTS
The most common RT-related toxicities were buccal mucositis
on the affected side occurring in 19 patients, dysphagia in 16,
and skin reaction in 14. Other minor toxicities included exter-
nal otitis, dry mouth, and nausea. All the toxicities were either
RTOG grade 1 or 2 affecting 53 patients (70.7%), and there
was no incidence of grade 3 or higher toxicity. 
At the time of analysis, 21 patients had relapsed: 20 patients
in the postoperative RT group; and one in the surgery alone
group. As the first site of failure, distant metastasis was the most
common observed in 17 patients, and there were three patients
with local recurrence and one with regional relapse (Fig. 1). The
sites of distant metastasis were the lung in 10 patients, the bone
in three, the brain in two, and other sites in two. Histologic types
of 17 patients with distant metastasis were salivary duct carcino-
ma in six, adenoid cystic carcinoma in six, adenocarcinoma in
two, carcinoma ex pleomorphic adenoma in two, and mucoepi-
dermoid carcinoma in one. One patient with simultaneous dis-
tant metastasis and regional neck node recurrence was with a
few risk factors: histologic type of salivary duct carcinoma; pT3;
EPE (+); and positive resection margin. Median time to distant
metastasis was 11 months (range, 3 to 34 months). The 5-yr
DFS rates were 74.4% and 94.7% in the postoperative RT and
the surgery alone groups. All patients who relapsed after post-
operative RT had high grade histology, and three patients had
local recurrence after 5, 10, and 13 months of surgery, whose
histologic types were salivary duct carcinoma in two and ade-
nocarcinoma in one. One patient with regional LN relapse after
surgery alone had refused postoperative RT recommended for
having pathologically proven LN metastasis. This patient received,
after regional recurrence, modified radical neck dissection fol-
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Table 3. Distribution of histological parameters according to the
treatment modalities
pT-Stage*
1 16 (21.3) 11 (57.9)
2 21 (28.0) 6 (31.6)
3 26 (34.7) 2 (10.5)
4 12 (16.0) 0
pN-Stage*
0 61 (81.3) 18 (94.7)
1 5 (6.7) 1 (5.3)
2 9 (12.0) 0
Resection margin
Negative 20 (26.7) 14 (73.7)
Close (<5 mm) 31 (41.3) 4 (21.0)
Positive 21 (28.0) 0
Unknown 3 (4.0) 1 (5.3)
Perineural invasion
Yes 14 (18.7) 0
No 60 (80.0) 19
Unknown 1 (1.3) 0
Lymphovascular invasion
Yes 12 (16.0) 1 (5.3)
No 62 (82.7) 18 (94.7)
Unknown 1 (1.3) 0
Extraparenchymal extension*
Yes 24 (32.0) 0
No 48 (64.0) 19
Unknown 3 (4.0) 0
Values are presented as number (%).
*According to American Joint Committee on Cancer 6th 2002.
RT: radiation therapy.
Fig. 1. Patterns of failure after postoperative radiotherapy in patients
with major salivary gland cancer.
Regional
1 (1.3%)
Distant
17 (22.7%)
11 6
Local
3 (4%)lowed by postoperative RT to the lymphatics, and there has
been no evidence of further recurrence until the last follow-up
at 9 months after salvage neck dissection. The 5-yr LC rates of
the postoperative RT and the surgery alone groups were 96.0%
and 100%, and the 5-yr OS rates were 78.2% and 100%. 
Table 4 shows results of univariate analysis for factors predic-
tive of DFS and OS. Old age (>50 yr), advanced pathologic T-
stage, positive pathologic N-stage, PNI, LVI, EPE, and high grade
tumor were significant prognostic factors affecting both DFS and
OS. Male sex was a significant factor affecting OS. On multi-
variate analysis, DFS was significantly affected by positive patho-
logic N-stage (hazard ratio [HR], 3.624; P=0.0319), while OS
was by positive pathologic N-stage (HR, 7.138; P=0.0034) and
PNI (HR, 5.073; P=0.0187) (Table 5).
DISCUSSION
The management of salivary gland cancer is primarily surgical.
Early stage major salivary gland cancer with low risk could be
effectively cured by surgical resection only. Chen et al. (9) reported
treatment results of 207 patients who were treated with surgery
alone for major salivary gland cancer. The 10-yr locoregional
control of patients with pathologic T1-2 disease was 80% and
that of patients without LN metastasis was 77%. LN metastasis
(HR, 4.8; P=0.001), high-grade tumor (HR, 4.2; P=0.003), posi-
tive surgical margins (HR, 2.6; P=0.03), and T3-4 disease (HR,
2.0; P=0.04) were significant independent predictors of locore-
gional control. In our study, surgery alone could achieve excel-
lent outcome in patients with low risk, except one patient who
refused postoperative RT despite of presence of pathologically
positive LN. Except this patient, there was no recurrence or
death in the surgery only group.
Patients with advanced T stage, high-grade tumor, positive
surgical margins, and LN metastasis usually receive postopera-
tive RT (4, 7, 13-15). In the treatment results of Terhaard et al.
(8), postoperative RT improved 10-yr LC significantly compared
with surgery alone in patients with T3-4 tumors (84% vs. 18%),
close resection margin (95% vs. 55%), incomplete resection (82%
vs. 44%), bone invasion (86% vs. 54%), and PNI (88% vs.
60%). LC rates at 5 and 10 yr were 94% and 91%, and with
ENI to 40% of patients (a median dose of 50 Gy), postopera-
tive RT also significantly improved regional control in patients
with pathological LN involvement (86% vs. 62%). Our study
showed 5-yr LC of 96.0% after postoperative RT, which is
comparable to the previous reports (4, 6, 8, 13, 14). Furthermore,
only one patient experienced regional failure after postopera-
tive RT who had simultaneous distant metastasis. Although we
did not administer ENI to clinically or pathologically negative
neck, this result is comparable to that of Terhaard et al, whose
10 yr regional control after postoperative RT was 93% for clin-
ically or pathologically N0 tumors (8).
Whether ENI should be applied routinely or not is still a con-
troversial issue in the salivary gland cancer patients with clini-
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Disease free survival Overall survival
Factors
P-value
Hazard ratio
P-value
Hazard ratio
(95% CI) (95% CI)
Table 5. Prognostic factors affecting survival outcomes on multi-
variate analysis
Age 0.2153 2.005 (0.667-6.026) 0.2760 2.170 (0.538-8.746)
Sex 0.1686 0.464 (0.156-1.384) 0.1477 0.307 (0.062-1.519)
pT-Stage* 0.6388 0.682 (0.138-3.367) 0.7259 1.379 (0.228-8.334)
pN-Stage* 0.0319 3.624 (1.118-11.749) 0.0034 7.138 (1.920-26.541)
PNI 0.1375 2.505 (0.746-8.413) 0.0187 5.073 (1.310-19.638)
LVI 0.5086 1.529 (0.434-5.382) 0.7560 1.249 (0.307-5.085)
EPE* 0.8338 1.201 (0.218-6.620) 0.6422 0.665 (0.119-3.709)
Grade 0.2250 3.793 (0.440-32.689) 0.9960 -
*According to American Joint Committee on Cancer 6th 2002.
CI: confidence interval; PNI: perineural invasion; LVI: lymphovascular inva-
sion, EPE: extraparenchymal extension.
Variables
Disease free survival Overall survival
5 yr rate (%) P-value 5 yr rate (%) P-value
Table 4. Prognostic factors affecting disease free survival and
overall survival on univariate analysis
Age (yr)
≤50 89.1 0.0175 92.9 0.0354
>50 68.6 73.0
Sex
Male 73.1 0.1041 71.7 0.0319
Female 86.6 97.4
pT-Stage*
1-2 86.7 0.0199 92.7 0.0203
3-4 67.4 69.3
pN-Stage*
0 84.6 0.0001 88.7 <0.0001
1-2 46.7 51.4
PNI
Yes 42.9 <0.0001 41.7 <0.0001
No 84.6 89.8
LVI
Yes 46.2 0.0005 51.3 0.0003
No 83.6 87.2
EPE*
Yes 53.9 0.0006 60.2 0.0003
No 86.4 90.0
Grade
Low 96.0 0.0161 100 0.0114
High 72.2 76.7
*According to American Joint Committee on Cancer 6th 2002.
PNI: perineural invasion; LVI: lymphovascular invasion, EPE: extra-
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cally negative neck. ENI should be considered when high risk is
suspected for subclinical nodal involvement. Histology, patho-
logic grade, and tumor size have been known to be the strongest
predictors of occult LN metastasis (10, 16-19). Santos et al. (18)
classified histological types into three groups according to the
risk for neck metastases, and the risks among the high risk
group were 85.7% in salivary duct carcinoma, 78.6% in squa-
mous cell carcinoma, 57.1% in high-grade mucoepidermoid
carcinoma, 55.6% in undifferentiated carcinoma, and 54.6% in
adenocarcinoma. In the study of Bhattacharyya et al., the high-
est increased odds ratios for nodal metastasis were exhibited in
facial nerve involvement (odd ratios [OR], 2.28; P=0.001), tumor
grade (OR, 1.99; P<0.001), and squamous cell carcinoma (OR,
2.17; P<0.001) (19). Similar results were reported in the study of
Chen et al. (9), and the risks of LN metastases without ENI were
67% in squamous cell carcinoma, 50% in undifferentiated carci-
noma, 34% in adenocarcinoma, and 29% in mucoepidermoid
carcinoma. There was no neck relapse among the patients with
adenoid cystic or acinic cell carcinoma regardless of ENI admin-
istration. Although based on rather small number of patients,
they suggested that ENI be beneficial in patients with salivary
duct carcinoma and carcinoma ex pleomorphic adenoma. 10-yr
nodal failure rate among the patients with T3-4 disease was
twice higher than that of T1-2 disease (13% vs. 6%, P=0.07),
and they concluded that ENI effectively prevented nodal relaps-
es and should be used for selected patients with high risk of
regional failure.
Before the decision about whether ENI should be adminis-
tered or not, accurate clinical evaluation of N-stage is crucial.
18F-FDG PET is known to have significant impact on the man-
agement of patients with salivary gland cancers for both the ini-
tial staging and the restaging (20, 21). Recently, Jeong et al.
(22) reported the diagnostic values from CT and PET/CT scans
in patients with high-grade salivary gland cancer. PET/CT pre-
dicted neck node metastasis more accurately than using only CT
(97.6% vs. 86.0%, P=0.01). Sensitivity and negative predictive
value were 100% for cervical LN metastasis. In addition, diag-
nostic accuracy of PET/CT for predicting the pathologic tumor
extent was 91.0%, which was also significantly higher than that
of CT alone (70.1%, P<0.001). Based on these, it may be spec-
ulated that the use of PET/CT has a major positive impact on
the clinical decision-making process for the patients with high-
grade salivary gland cancer. 
Although excellent local or regional control could be achieved
after postoperative RT, the majority of treatment failures were
distant metastases. Additional distant metastases can be detect-
ed by longer follow-up because distant metastases in salivary
gland cancer often occur at over 5 yr and follow-up period was
relatively short in current study (23, 24).  Improvements in systemic
therapy are needed to overcome distant metastasis. Recently, one
study regarding trastuzumab therapy for salivary gland carcino-
ma was published (25). Three patients with recurrence, whose
tumors were positive for human epidermal growth factor receptor
2 (HER-2) on fluorescence in situ hybridization, received trastuzum-
ab therapy. One of three patients died after 20 months and the
other two were alive at 19 and 36 months, respectively. One of
the latter patients has shown disappearance of pulmonary nod-
ules via repeat CT and PET and has remained disease free for 3
yr on trastuzumab. Like this results, HER-2 is a potential target in
salivary duct carcinoma. In addition, epidermal growth factor
receptor can be a molecular target in adenoid cystic carcinoma,
mucoepidermoid carcinoma, and salivary duct carcinoma (26).
Further studies of agents targeting these receptors are warranted.
In conclusion, early stage major salivary gland cancer with
low risk can be effectively treated by surgical resection only.
And patients who had risk factors after surgical resection achieved
excellent local and regional control after adding postoperative
RT. Under accurate clinical evaluation and appropriate patient
selection, omitting ENI in clinically or pathologically N0 disease
can be a feasible strategy in patients without risk factors for sub-
clinical nodal involvement. An effort is needed to decrease dis-
tant metastasis through further clinical trials.
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